HAX1 and laryngeal carcinoma: Moreover, Liu et al. [14] found that miR-125a was decreased in laryngeal carcinoma tissues and Hep-2 laryngeal cancer stem cells (Hep-2-CSCs) and re-expressing miR-125a enhanced the the sensitivity of Hep-2-CSCs to cisplatin in laryngeal cancer stem cells by targeting HAX-1.